Deciphera Pharma

We’re happy to announce that we are presenting two posters at #EMSOS26! These e-posters explore the long-term efficacy and safety of medicine for patients with #TGCT. Learn more about EMSOS: emsos2026.pt

Happy #WorldHealthDay from our team at Deciphera. Celebrated each year on April 7, this day marks the anniversary of the @WHO, founded in 1948 to advance health and well-being for people around the world. This year’s theme, “Together for health. Stand with science,” is one that resonates deeply with our organization. At Deciphera, patients are at the center of everything we do, and we believe that collective scientific innovation plays a critical role in helping patients live longer, healthier lives. Learn more about World Health Day and the WHO here: lnkd.in/eJEwHzbT

Today, @Ono_pharma_PR, the parent company of Deciphera, announced that it has submitted an application for approval of ripretinib in patients with advanced gastrointestinal stromal tumor (#GIST) in Japan. Read the press release here: bit.ly/4t8u9hB

We had a great time connecting with colleagues, clinicians, and researchers at the @myESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland. Our team was proud to share insights from our vimseltinib and ripretinib programs, contributing to important conversations around innovation in sarcoma and rare cancers. A huge thank you to the organizers, speakers, and everyone who stopped by to engage with our team. We look forward to continuing the dialogue as we advance our work across oncology.

We are pleased to announce that the @US_FDA has accepted our New Drug Application (NDA) under the accelerated approval pathway for our a highly selective irreversible, second generation Bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL). This is an exciting milestone for our company and the patients we serve as R/R PCNSL often results in poor outcomes for patients. To read the press release and learn more, visit: bit.ly/3MfpydT

Our team is headed to Salt Lake City, UT to attend the @ASTCT’s TANDEM Annual Meeting! During the conference, we will present a poster on our Phase 2 open label study in adults with active chronic #GvHD after failure of prior systemic therapies. If you’re in town for #TANDEM26, we hope to see you there! To learn more about this conference, visit: lnkd.in/gnp7xeVJ #GeneTherapy #CellularTherapy #HCT

For those diagnosed with cancer, it can often feel like their world has been turned upside down. On #WorldCancerDay, Deciphera and @Ono_pharma_PR are proud to join the global community in the #UpsideDownChallenge, which highlights the unique experiences that cancer patients, survivors, family and friends face. Today and every day, the Ono Group is committed to supporting patients by advancing the discovery and development of innovative medicines. To learn more about World Cancer Day, visit:  worldcancerday.org #UnitedByUnique

Today, @Ono_pharma_PR the parent company of Deciphera, announced its financial results for the third quarter 2025. Read more: lnkd.in/eaVSGucr

We were proud to see Toichi Takino, President and COO of @Ono_pharma_PR, take the stage at the @JPMorgan Healthcare Conference, sharing a compelling vision for the Ono Group's future. The presentation highlighted the strength of our pipeline, the momentum of our commercial products, and the significant growth opportunities ahead. Exciting times as Ono continues to execute its strategy and deliver long-term value. To listen to a replay of the presentation, visit: bit.ly/3LzAbaZ #JPM26

Today we announced the oral presentation of positive results from the Phase 2a IMPRSSION study in polycythemia vera at hashtag#ASH25! We look forward to sharing the results from this study and advancing this promising investigational treatment towards Phase 3. Read the press release: lnkd.in/egWw-hrX

We have six posters at #CTOS2025! Our team is in Boca Raton sharing data across our multiple pipeline programs, including the long-term and safety results from our MOTION Phase 3 study in #TGCT. We are excited to be at this gathering of #sarcoma specialists and look forward to sharing insights from our data. Read the press release and learn more: bit.ly/47R9plz

Today, @Ono_pharma_PR, the parent company of Deciphera, announced its financial results for the second quarter 2025. Read more: bit.ly/3X3dA8J

We’re presenting at #ESMO25! Join us in Berlin for our poster presentation on the long-term safety and efficacy results of our Phase 3 MOTION trial of vimseltinib. To read the full results, visit: bit.ly/4qzjaxp #CancerResearch #TGCT

This week, Our Chief Commercial Officer will participate in a panel during the Zug Pharma Group 2025 Zug Life Science Summit! During the event, she will share her perspective on her visions for the #lifesciences industry in Zug. Learn more: lnkd.in/eQm9GMHs #ZugSummit25

#DidYouKnow that nearly 1 in 4 cancer diagnoses is rare? September 30th marks #RareCancerDay, an annual awareness day devoted to shining a light on rare cancers like #GIST. Learn more about @RareDiseases and the Rare Cancer Day initiative here: lnkd.in/eh2gwb8J

Behind our extensive oncology pipeline is a talented group of scientists, clinicians, and researchers dedicated to delivering transformational medicines that have a meaningful impact on patients. We’re excited about what we’ve achieved so far in #cancerresearch, and look forward to continuing to raise the bar for patients in #oncology. #WorldCancerResearchDay Learn more about our work: deciphera.com

We are excited about the recent European Commission approval of our new medicine for people living with tenosynovial giant cell tumor (#TGCT)! Learn more: lnkd.in/ed5zs6sQ #CancerResearch

We’re proud to announce the @EU_Commission approval of our medicine for patients with symptomatic tenosynovial giant cell tumor (#TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability. Learn more at our press release here: lnkd.in/ed5zs6sQ

Patients with tenosynovial giant cell tumor (#TGCT) can experience substantial symptomatic burdens including pain and stiffness, impaired physical function and limited range of motion, which negatively impacts quality of life. Learn more about Deciphera’s commitment to advancing research in this disease: bit.ly/3UFuTvm

Today, @Ono_pharma_PR, the parent company of Deciphera, announced its financial results for the first quarter 2025. Read more: bit.ly/47bE4Lw